Visit our parent company, HiberCell.

Accelerating Discovery in CNS, Cardiometabolic and Inflammatory Disease

We support our clients to achieve more in their target & biomarker programmes. Our expertise, curated & disease enriched clinco-omic cohorts, tools and applications for insight generation, enable our clients to prioritise and accelerate discovery research & development.

Learn More

Our Capabilities & Expertise

Target Discovery

Target Discovery

Identify novel targets with strong genetic evidence

Portfolio Optimization

Portfolio Optimization

Validate candidate targets or biomarkers and focus investment

Clinical Trials

Clinical Trials

Design better studies and enrolment criteria by identifying relevant sub-populations

Biomarker Discovery

Biomarker Discovery

Discover novel biomarkers that enable higher resolution disease stratification

Global Disease Datasets

Alzheimer's

Diabetic and Non-diabetic Nephropathy

Heart Failure

Inflammatory Bowel Disease

Liver Disease

Lupus

Multiple Sclerosis

Parkinson's

Our Approach

Genuity Science brings purpose-driven data and genomic know-how to catalyze insights and drive better drug discovery decisions.

Genuity Science Icon

Significantly
Powered Datasets

We combine retrospective and prospective population-based disease-specific datasets powered for statistical significance to create a robust picture of disease providing stronger signals for clearer conclusions.

High-Quality Deeply Phenotyped Whole Genomes

Our high-quality whole genome sequence approach is coupled with deep phenotypic data fuelling our advanced analysis - taking insight a step further.

Population-Scale
Expertise

Our expertise in massive, population-scale datasets and deep learning methods is enhanced by expertise in the industry’s only data analysis platform built for population-scale genomics.

Longitudinal Data

Longitudinal insight illuminates disease progression over time for a more comprehensive picture of the disease.

Partner Spotlight


 

Ionis Pharmaceuticals and Genuity Science have partnered on the discovery of up to 20 novel targets rooted in the underlying biology of a range of diseases.

“I’m convinced that the way Genuity Science is working is the future of genomic research.”

Hear from Leo Saheljio, MD, VP of Translational Medicine on the announcement of the collaboration, and why Ionis chose Genuity Science as a partner for this work.